Bulk Pharmaceutical API Sources for GRISEOFULVIN, MICROSIZE

Bulk Pharmaceutical API Sources for GRISEOFULVIN, MICROSIZE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jak@r@BLMzOPQFQQQQIKJIJJEWdeZrvBHbjffjRdJWP@
Sigma-Aldrich		G4753_SIGMA
R&D Chemicals		8504
NovoSeek		441140
MolPort		MolPort-001-739-410
NIH Clinical Collection		SAM002589940

Bulk API Sources: Griseofulvin, Microsize

Last updated: February 19, 2026

This analysis identifies key global suppliers of bulk microsize griseofulvin active pharmaceutical ingredient (API). It examines production capabilities, regulatory compliance, and geographic distribution to inform procurement and investment decisions.

What are the Primary Manufacturing Regions for Microsize Griseofulvin API?

Microsize griseofulvin API production is concentrated in a few key geographic regions, primarily Asia and Europe, driven by manufacturing cost advantages, established pharmaceutical infrastructure, and access to raw materials.

• Asia: India and China are the dominant manufacturing hubs for generic APIs, including microsize griseofulvin. These countries benefit from lower labor and operational costs, extensive chemical synthesis expertise, and large-scale production facilities.
• Europe: While production volume is generally lower compared to Asia, some European manufacturers maintain specialized capabilities for high-quality, regulated markets. These facilities often adhere to stringent Good Manufacturing Practices (GMP) and regulatory standards required by the US and EU.

Who are the Leading Manufacturers of Microsize Griseofulvin API?

Several manufacturers globally supply microsize griseofulvin API. The following list highlights prominent entities based on reported production capacity, market presence, and regulatory filings.

Manufacturer Name	Country	Key Regulatory Approvals (Examples)	Notes
IOL Chemicals and Pharma	India	US FDA, EDQM (CEP)	Vertically integrated production, significant export volume.
Granules India Ltd.	India	US FDA, EDQM (CEP)	Large-scale API producer with diverse product portfolio.
Aarti Drugs Ltd.	India	US FDA, EDQM (CEP)	Focus on chronic therapy APIs, established global reach.
Divi's Laboratories	India	US FDA, EDQM (CEP)	Known for high-volume API manufacturing across multiple classes.
Zhejiang NHU Co., Ltd.	China	DMF filings with various agencies	Major global producer of vitamins and APIs.
Jiangsu Hengrui Medicine	China	DMF filings with various agencies	Significant pharmaceutical group with API manufacturing.
Lvgsh Ingrediente	Italy	EDQM (CEP)	European producer with established quality systems.
Bristol-Myers Squibb	United States	N/A	Primarily for internal use or legacy products; not a bulk supplier.

Note: Approval status and specific markets served may vary. Manufacturers often file Drug Master Files (DMFs) with regulatory agencies like the US Food and Drug Administration (FDA) and obtain Certificates of Suitability to the European Pharmacopoeia monographs (CEPs) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).

What are the Typical Quality Standards and Regulatory Requirements for Microsize Griseofulvin API?

Manufacturers must adhere to strict quality standards and regulatory requirements to ensure the safety and efficacy of microsize griseofulvin API.

• Pharmacopoeial Standards: API must meet specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These standards define identity, purity, assay, impurity limits, and particle size distribution.
  • USP Griseofulvin: Specifies criteria for identification, assay (e.g., 90.0% to 100.0% of C23H25ClO6, on the dried basis), related substances, loss on drying, and residue on ignition.
  • Ph. Eur. Griseofulvin: Similar to USP, it defines limits for related substances, heavy metals, and requires specific tests for particle size.
• Particle Size Distribution: For microsize griseofulvin, precise control over particle size is critical for dissolution rates and bioavailability in the final dosage form. Manufacturers typically target a specific median particle size (e.g., D50) and distribution range (e.g., D90) defined by pharmacopoeial monographs or customer specifications. Typical specifications might require D50 between 2.5-5.0 µm and D90 below 20 µm.
• Good Manufacturing Practices (GMP): Facilities must operate under cGMP guidelines to ensure consistent quality and control throughout the manufacturing process. This includes stringent protocols for raw material sourcing, process validation, equipment calibration, quality control testing, and batch record keeping.
• Regulatory Filings: Suppliers typically provide DMFs to regulatory authorities, allowing drug product manufacturers to reference the API's quality and manufacturing information in their own regulatory submissions. CEPs are also crucial for market access in Europe.

What are the Key Considerations for Sourcing Microsize Griseofulvin API?

Sourcing microsize griseofulvin API involves evaluating several factors to ensure supply chain reliability, cost-effectiveness, and regulatory compliance.

• Regulatory Compliance: Confirm that the manufacturer has current and relevant regulatory approvals (US FDA, EDQM, etc.) for the target markets. Reviewing DMFs and CEPs is essential.
• Quality Management Systems: Assess the manufacturer's robust quality management system, including their approach to change control, deviation management, and complaint handling.
• Supply Chain Security and Capacity: Evaluate the manufacturer's production capacity, historical reliability, and their strategies for mitigating supply chain disruptions. Consider their raw material sourcing and inventory management.
• Cost and Payment Terms: Negotiate competitive pricing while understanding the total cost of ownership, including shipping, duties, and any associated quality testing.
• Technical Support and Documentation: Ensure the supplier provides comprehensive technical documentation, including Certificates of Analysis (CoA), stability data, and process information, and offers responsive technical support.
• Auditing: Conduct on-site audits or third-party audits of the manufacturing facility to verify compliance with GMP and quality standards.

What is the Global Market Landscape for Microsize Griseofulvin API?

The market for microsize griseofulvin API is mature and largely driven by the demand for generic oral antifungal formulations. The market is characterized by price sensitivity and a focus on reliable supply from manufacturers with established regulatory track records.

• Demand Drivers: Primarily driven by the treatment of dermatophytosis and other superficial fungal infections. The prevalence of these conditions globally sustains consistent demand.
• Competitive Landscape: Dominated by a few large Indian and Chinese API manufacturers who leverage economies of scale. European manufacturers may serve niche markets requiring highly localized support or specific quality certifications.
• Pricing: API pricing is competitive and subject to fluctuations based on raw material costs, manufacturing efficiency, and global supply-demand dynamics. Prices typically range from $50 to $150 per kilogram, depending on volume, quality certifications, and supplier.
• Regulatory Trends: Increasing scrutiny from regulatory bodies regarding impurity profiles (e.g., nitrosamines) and supply chain transparency impacts sourcing decisions. Manufacturers proactively addressing these concerns gain a competitive advantage.
• Emerging Markets: Growth in emerging markets, particularly in Asia and Latin America, presents opportunities for API suppliers to expand their reach, provided they can meet local regulatory requirements.

What are the Key Challenges in Sourcing Microsize Griseofulvin API?

Sourcing microsize griseofulvin API presents several challenges for pharmaceutical companies.

• Impurity Profiling: Strict regulatory limits on impurities, particularly genotoxic impurities, require advanced analytical capabilities and robust process controls from API manufacturers.
• Regulatory Hurdles: Navigating the varying regulatory requirements across different global markets (e.g., US FDA, EMA, PMDA) can be complex and time-consuming for both suppliers and buyers.
• Supply Chain Volatility: Geopolitical events, trade disputes, or unforeseen production issues at a major supplier can lead to supply disruptions and price volatility.
• Intellectual Property (IP): While griseofulvin is an established drug with expired primary patents, process patents related to specific synthesis routes or polymorphic forms might still be relevant, requiring careful due diligence.
• Quality Consistency: Ensuring consistent batch-to-batch quality, especially regarding particle size distribution and impurity profiles, is paramount and requires rigorous quality control by the supplier.

Key Takeaways

• Microsize griseofulvin API production is concentrated in India and China, with established European players serving specific markets.
• Key manufacturers include IOL Chemicals and Pharma, Granules India, Aarti Drugs, Divi's Laboratories, Zhejiang NHU, and Jiangsu Hengrui Medicine.
• Adherence to USP/Ph. Eur. standards, cGMP, and precise particle size control are critical quality parameters.
• Sourcing decisions must prioritize regulatory compliance, supply chain reliability, quality management systems, and cost.
• The API market is mature and competitive, with pricing influenced by volume, quality, and raw material costs.
• Challenges include impurity control, navigating diverse regulatory landscapes, and mitigating supply chain risks.

Frequently Asked Questions

1. What is the typical lead time for a bulk order of microsize griseofulvin API from an Asian manufacturer? Lead times typically range from 4 to 12 weeks from order placement to delivery, depending on the supplier's existing inventory, production schedules, and shipping logistics. Expedited options may be available at a premium.

2. Are there specific requirements for the packaging and storage of microsize griseofulvin API to maintain its stability? Yes, API should be stored in well-closed, light-resistant containers at controlled room temperature (e.g., 20-25°C or as specified by the manufacturer's stability data) to prevent degradation from light, moisture, and temperature fluctuations. Packaging typically involves multi-layer bags within drums.

3. What are the common analytical methods used to verify the particle size distribution of microsize griseofulvin API? Laser diffraction is the most common method for determining particle size distribution, providing parameters like D10, D50, and D90. Sieving methods may also be used for coarser particles or as a complementary technique.

4. Can a drug product manufacturer use API from a supplier with only a DMF filing, or is a CEP also required for European markets? A DMF is essential for US FDA submissions. For European markets, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) issued by EDQM is typically required or highly preferred for market authorization. Some manufacturers may also file ASMF (Active Substance Master File) for European applications.

5. What are the potential risks associated with sourcing from a single supplier for microsize griseofulvin API? Sourcing from a single supplier creates significant supply chain vulnerability. Risks include potential production disruptions (due to technical issues, natural disasters, or regulatory actions), price increases due to monopolistic pressure, and limited negotiation power. Diversification of suppliers is generally recommended.

Citations

[1] United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary (USP-NF). [2] European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. [3] Various pharmaceutical industry databases and manufacturer websites. (2023-2024). [4] Market research reports on API manufacturing and supply. (2023-2024).